LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 19 August 2016, a notice has been received from the China Food and Drug Administration (the "**CFDA**") formally approving the Group's application of the innovative medical device status, which is also known as the "CFDA green channel" (the "**Status**"), for the Group's products (the "**Products**") namely, (i) the HeartTone™ pacemaker, and (ii) the IrisFIT™ patent foramen ovale occluder (the "**IrisFIT™ PFO occluder**") in accordance with CFDA's Procedures for Special Approval of Innovative Medical Devices (Trial) No. 13 (2014) (食品藥品監管總局關於印發創新醫療器械特別審批程序(試行) [2014] 13號).

Given the Status has been approved, the CFDA will provide additional support and assistance to the Group for the registration of the Products. In particular, the Center for Medical Device Evaluation of the CFDA will designate an officer for communications and discussions on the technical issues with the Group and priority will be given by the CFDA to the Products for their technical review and subsequent registration approval in future. In addition, the relevant medical device testing institution shall, upon receipt of the samples of the Products, prioritise the medical device registration tests of the Products and then issue their respective test reports. The Status will accelerate the registration procedures of the Products in the People's Republic of China ("**PRC**").

Information about the HeartTone™ Pacemaker

In July 2014, the Group expanded its strategic collaboration with Medtronic Inc. or its affiliates (collectively known as "**Medtronic**"), one of the world's largest medical

technology companies offering an unprecedented breadth and depth of innovative therapies. Pursuant to several agreements entered into between the Group and Medtronic, Medtronic shall provide necessary technical, operational and management expertise to the Group on the manufacturing and market release of the HeartTone™ pacemaker. In June 2016, the Group's first manufacturing line of the HeartTone™ pacemaker, which was designed and built under the guidance of Medtronic, has satisfied the manufacturing line qualification requirements, thereby demonstrated that it met the quality standards of Medtronic.

Information about the IrisFIT™ PFO occluder

IrisFIT™ PFO occluder is designed for patent foramen ovale ("**PFO**") patients associated with recurrent transient ischemic attack or cryptogenic stroke. IrisFIT™ PFO occluder owns global independent intellectual property rights, which represent the leading technology in the industry, and has obtained the Conformité Européenne certification approval in 2012 upon completion of its clinical trial in Germany and France. The metal surface of IrisFIT™ PFO occluder adopts nano-scale Titanium Nitride coating technology, which reduces nickel elution and thereby effectively decreasing the occurrence of postoperative complications and speeding endothelialisation. The unique braided anchor design of its left disc minimises the use of metal material which can reduce the occurrence of clots at the left atrium. The waist of the IrisFIT™ PFO occluder can be automatically adjusted on its own length and orientation according to the length of the patient's PFO channel, enabling its use on patients with extremely long PFO channel. In addition, fibers around the waist of the IrisFIT™ PFO occluder ensure it can quickly stop blood shunt in PFO channel after being implanted and thereby achieving ideal and optimal occlusion performance.

The Board believes that the guidance and support to be provided by the CFDA on the registration procedures of both the HeartTone™ pacemaker and the IrisFIT™ PFO occluder will help achieve cost-effectiveness and time-efficiency on satisfying the CFDA registration requirements.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 22 August 2016

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. XIAO Ying being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.